BridgeBio Pharma, Inc. (NASDAQ:BBIO) Discusses Constructive FORTIFY Part III Interim Leads to Limb-Girdle Muscular Dystrophy Sort 2I/R9 October 27, 2025 8:00 AM EDT
Firm Members
Neil Kumar – Co-Founder, CEO & Director
Christine Siu
Douglas Sproule
Uma Sinha – Chief Scientific Officer
Matthew Outten – Chief Business Officer
Convention Name Members
Tyler Van Buren – TD Cowen, Analysis Division
Salim Syed – Mizuho Securities USA LLC, Analysis Division
Cory Kasimov – Evercore ISI Institutional Equities, Analysis Division
Mani Foroohar – Leerink Companions LLC, Analysis Division
Joshua Schimmer – Cantor Fitzgerald & Co., Analysis Division
Biren Amin – Piper Sandler & Co., Analysis Division
Lin Tsai – Jefferies LLC, Analysis Division
Danielle Brill Bongero – Truist Securities, Inc., Analysis Division
Anupam Rama – JPMorgan Chase & Co, Analysis Division
Kyuwon Choi – Goldman Sachs Group, Inc., Analysis Division
Jason Zemansky – BofA Securities, Analysis Division
Presentation
Operator
Girls and gents, thanks for standing by. My title is Krista, and I will probably be your convention operator right now. Presently, I want to welcome everybody to the BridgeBio Pharma Limb-Girdle Muscular Dystrophy Sort 2i/R9 FORTIFY Part III Interim Evaluation Outcomes Webinar. [Operator Instructions] Thanks.
I might now like to show the convention over to Dr. Neil Kumar, Chief Govt Officer. Dr. Kumar, please go forward.
Neil Kumar
Co-Founder, CEO & Director
Thanks, everybody, for becoming a member of this name. Along with our wonderful group, I am grateful to have the ability to share with you on behalf of the extraordinary physicians, sufferers, households and caregivers concerned, the constructive Part III outcomes of our FORTIFY scientific trial for sufferers with limb-girdle muscular dystrophy kind 2i. The strongly constructive and constant knowledge the neighborhood work tirelessly to generate come collectively at this second to portend a brand new and higher day for present and future sufferers scuffling with this situation.
Earlier than I set the company context for this
